| scholarly article | Q13442814 |
| P2093 | author name string | Gunilla Westermark | |
| Per Westermark | |||
| Kerstin Berntorp | |||
| Valdemar Grill | |||
| Michael Alvarsson | |||
| Göran Sundkvist | |||
| Thomas Orn | |||
| Lars Steen | |||
| Marianne Henricsson | |||
| Eva Fernqvist-Forbes | |||
| Ibe Lager | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | preproinsulin | Q7240673 |
| P304 | page(s) | 2231-2237 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients | |
| P478 | volume | 26 |
| Q35529658 | A randomized, open-label, comparative crossover handling trial between two durable pens in patients with type 1 or 2 diabetes mellitus |
| Q42933616 | Barriers to achieving glycemic targets: who omits insulin and why? |
| Q36906173 | Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy |
| Q37101311 | Beta cell mass in diabetes: a realistic therapeutic target? |
| Q45247800 | Cardiac-derived adiponectin induced by long-term insulin treatment ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic mice via AMPK signaling |
| Q38115799 | Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
| Q35651511 | Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications |
| Q38071018 | Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues |
| Q37624279 | Early insulin treatment in type 2 diabetes: what are the pros? |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q46576386 | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. |
| Q46967291 | Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria |
| Q37875220 | Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes |
| Q34594675 | Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes |
| Q34703169 | Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study |
| Q51474263 | Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. |
| Q34064416 | Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus |
| Q86582910 | Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes |
| Q36071183 | Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials |
| Q38536492 | Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis. |
| Q36690218 | First approved inhaled insulin therapy for diabetes mellitus |
| Q34106145 | Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells |
| Q46632541 | Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids: a randomised controlled trial |
| Q46919852 | Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal |
| Q34585855 | Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding |
| Q54353931 | Insulin therapy improves islet functions by restoring pancreatic vasculature in high-fat diet-fed streptozotocin-diabetic rats. |
| Q37364992 | Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial |
| Q39309680 | Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? |
| Q37364945 | Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? |
| Q36975546 | Intensive intravenous infusion of insulin in diabetic cats |
| Q42730182 | International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece |
| Q24234365 | Interventions for latent autoimmune diabetes (LADA) in adults |
| Q24244270 | Interventions for latent autoimmune diabetes (LADA) in adults |
| Q37031010 | Npas4 is a novel activity-regulated cytoprotective factor in pancreatic β-cells. |
| Q41054906 | Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q37351709 | Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control |
| Q37516034 | Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q35123342 | Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission |
| Q38190489 | Sulfonylureas: a new look at old therapy |
| Q24186660 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q24197884 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q97643514 | Targeted pharmacological therapy restores β-cell function for diabetes remission |
| Q38038658 | The diabetic β-cell: hyperstimulated vs. hyperexcited |
| Q38442291 | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. |
| Q80442170 | The pathophysiological basis for intensive insulin replacement |
| Q51158595 | Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. |
| Q34219402 | We can change the natural history of type 2 diabetes |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
Search more.